Thursday, November 12, 2026

Silver Price Analysis: XAG/USD Keeps Bounce Off 100-DMA Above $24.00 To Favor Bulls: (SI) Is 7% Up In The Last 10 Sessions

Via News Just in

August 28, 2023

Silver Price Analysis: XAG/USD Keeps Bounce Off 100-DMA Above $24.00 To Favor Bulls: (SI) Is 7% Up In The Last 10 Sessions
(VIANEWS) - Silver Price (XAG/USD) picks up bids to $24.30 as it defends the previous day's rebound from the 100-DMA amid the early hours of Monday's Asian trading session. FXStreet reported that in addition to the XAG/USD's U-turn from the 100-DMA, the bullish MACD signals and firmer RSI (14), not overbought, also underpin bullish bias about the bright metal. However, a horizontal area comprising multiple levels marked since January 2023, close to $24.50, appears a tough nut to crack for the Silver buyers. Silver (SI) has been up by 7.88% for the last 10 sessions. At 08:51 EST on Monday, 28 August, Silver (SI) is $24.22.

Silver price analysis: xag/usd keeps bounce off 100-dma above $24.00 to favor bulls

Overall, the Silver price remains on the buyer's radar even if the upside road remains long and bumpy., However, a horizontal area comprising multiple levels marked since January 2023, close to $24.50, appears a tough nut to crack for the Silver buyers.

Volume

Today's last reported volume for Silver is 10866, 99.99% below its average volume of 12152352817.03.

Volatility

Silver's last week, last month's, and last quarter's current intraday variation average was 1.16%, 0.28%, and 1.17%, respectively. Silver's highest amplitude of average volatility was 1.53% (last week), 1.01% (last month), and 1.17% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Silver's commodity is considered to be oversold (<=20). More news about Silver (SI).
Via News Just in

Breaking news and real-time updates on financial markets, business developments, and economic events from Via News.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com